TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 321.3M
Gross Profit 177.8M 55.33%
Operating Income 16.0M 4.97%
Net Income 6.0M 1.88%
EPS (Diluted) $0.19

Balance Sheet Metrics

Total Assets 2.3B
Total Liabilities 1.3B
Shareholders Equity 977.6M
Debt to Equity 1.35

Cash Flow Metrics

Operating Cash Flow 49.7M
Free Cash Flow 37.8M

Revenue & Profitability Trend

Conmed Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i1.3B1.2B1.0B1.0B862.5M
Cost of Goods Sold i574.0M568.5M474.2M442.6M402.2M
Gross Profit i733.0M676.2M571.2M568.0M460.3M
Gross Margin % i56.1%54.3%54.6%56.2%53.4%
Operating Expenses
Research & Development i54.4M52.6M47.2M43.6M40.5M
Selling, General & Administrative i478.3M503.0M454.0M414.8M373.8M
Other Operating Expenses i-----
Total Operating Expenses i532.7M555.6M501.2M458.3M414.3M
Operating Income i200.3M120.6M70.1M109.7M46.0M
Operating Margin % i15.3%9.7%6.7%10.9%5.3%
Non-Operating Items
Interest Income i-----
Interest Expense i37.3M39.8M28.9M35.5M44.1M
Other Non-Operating Income---112.0M-1.1M-355.0K
Pre-tax Income i163.0M80.8M-70.9M73.1M1.6M
Income Tax i30.6M16.4M9.7M10.6M-7.9M
Effective Tax Rate % i18.8%20.3%0.0%14.4%-493.7%
Net Income i132.4M64.5M-80.6M62.5M9.5M
Net Margin % i10.1%5.2%-7.7%6.2%1.1%
Key Metrics
EBITDA i272.2M192.5M27.6M179.3M118.3M
EPS (Basic) i$4.29$2.10$-2.68$2.14$0.33
EPS (Diluted) i$4.25$2.04$-2.68$1.94$0.32
Basic Shares Outstanding i3084600030668000300400002916200028581000
Diluted Shares Outstanding i3084600030668000300400002916200028581000

Income Statement Trend

Conmed Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i24.5M24.3M28.9M20.8M27.4M
Short-term Investments i-----
Accounts Receivable i237.7M242.3M191.3M183.9M177.2M
Inventory i346.7M318.3M332.3M231.6M194.9M
Other Current Assets31.1M30.8M28.6M23.8M17.3M
Total Current Assets i640.0M615.6M581.2M460.1M416.7M
Non-Current Assets
Property, Plant & Equipment i00000
Goodwill i2.2B2.3B2.3B1.7B1.7B
Intangible Assets i617.7M649.5M681.8M471.0M501.5M
Long-term Investments-----
Other Non-Current Assets127.4M107.3M103.5M108.5M103.6M
Total Non-Current Assets i1.7B1.7B1.7B1.3B1.3B
Total Assets i2.3B2.3B2.3B1.8B1.8B
Liabilities
Current Liabilities
Accounts Payable i102.2M88.2M73.4M58.2M53.3M
Short-term Debt i715.0K708.0K69.7M12.2M18.4M
Current Portion of Long-term Debt-----
Other Current Liabilities109.8M151.7M98.7M65.7M68.3M
Total Current Liabilities i278.1M310.7M296.6M196.6M190.2M
Non-Current Liabilities
Long-term Debt i905.1M973.1M985.1M672.4M735.2M
Deferred Tax Liabilities i74.1M60.9M66.7M68.5M57.9M
Other Non-Current Liabilities86.3M121.0M203.7M43.0M59.3M
Total Non-Current Liabilities i1.1B1.2B1.3B783.9M852.4M
Total Liabilities i1.3B1.5B1.6B980.6M1.0B
Equity
Common Stock i313.0K313.0K313.0K313.0K313.0K
Retained Earnings i560.3M452.5M412.6M496.6M457.4M
Treasury Stock i15.6M15.0M22.8M54.1M67.6M
Other Equity-----
Total Shareholders Equity i962.7M834.2M745.5M785.4M709.0M
Key Metrics
Total Debt i905.8M973.8M1.1B684.7M753.6M
Working Capital i361.9M304.9M284.7M263.5M226.5M

Balance Sheet Composition

Conmed Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i132.4M64.5M-80.6M62.5M9.5M
Depreciation & Amortization i71.9M71.9M69.5M70.7M72.6M
Stock-Based Compensation i25.6M24.3M21.7M16.3M13.1M
Working Capital Changes i-39.7M-39.6M-90.7M-55.7M-29.9M
Operating Cash Flow i167.0M125.3M24.5M110.9M64.5M
Investing Activities
Capital Expenditures i-13.1M-19.0M-21.8M-14.9M-9.8M
Acquisitions i00-227.7M0-3.9M
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i-13.1M-20.0M-249.5M-14.9M-13.6M
Financing Activities
Share Repurchases i-----
Dividends Paid i-24.7M-24.5M-24.0M-23.3M-22.8M
Debt Issuance i751.0M692.0M1.3B379.2M199.0M
Debt Repayment i-823.0M-780.0M-898.0M-460.4M-225.2M
Financing Cash Flow i-151.0M-110.4M222.5M-168.5M-65.1M
Free Cash Flow i153.9M106.3M11.6M96.9M51.5M
Net Change in Cash i2.9M-5.1M-2.5M-72.5M-14.2M

Cash Flow Trend

Conmed Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 13.40
Forward P/E 10.55
Price to Book 1.62
Price to Sales 1.20
PEG Ratio 10.55

Profitability Ratios

Profit Margin 9.02%
Operating Margin 7.27%
Return on Equity 12.96%
Return on Assets 4.14%

Financial Health

Current Ratio 2.26
Debt to Equity 91.26
Beta 1.21

Per Share Data

EPS (TTM) $3.81
Book Value per Share $31.61
Revenue per Share $42.60

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
cnmd1.6B13.401.6212.96%9.02%91.26
Abbott Laboratories 219.8B15.854.5027.98%32.43%27.09
Boston Scientific 157.5B63.387.098.42%13.55%52.16
UFP Technologies 1.8B28.514.9619.36%11.59%55.05
QuidelOrtho 1.8B-0.800.59-11.38%-12.97%90.01
Alphatec Holdings 1.6B-9.63-18.581,144.21%-25.77%-6.76

Financial data is updated regularly. All figures are in the company's reporting currency.